Last reviewed · How we verify
NCT06788171
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
Phase 2 trial testing Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy in Colorectal Cancer Liver Metastasis in 35 participants. Not yet recruiting.
1 December 2026
Quick facts
| Lead sponsor | Fujian Cancer Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 1 March 2025 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy
- Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
- Capecitabine (capecitabine) — full drug profile →
- Oxaliplatin (Oxaliplatin) — full drug profile →
- Sintilimab — full drug profile →
Conditions studied
- Colorectal Cancer Liver Metastasis — all drugs for Colorectal Cancer Liver Metastasis →
Sponsor
Fujian Cancer Hospital
Who can join
Adults 18 to 75, any sex, with Colorectal Cancer Liver Metastasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To explore Progression-Free-Survival(FPS) of PULSAR(personalized ultrafractionated stereotactic adaptive radiotherapy) combined with PD-1 Ab and Chemotherapy plus Bevacizumabfor CRLM
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06788171
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer Liver Metastasis
Currently open trials in the same condition.
- NCT07392567 — Prospective Validation of an AI Model for Predicting Liver Metastasis in Colorectal Cancer · recruiting
Other Fujian Cancer Hospital trials
Trials by the same sponsor.
- NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
- NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
- NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06788171 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
- Last refreshed: 23 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06788171.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing